Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
+11.96%
$0.93
100% positive prob.
5-Day Prediction
+23.99%
$1.03
100% positive prob.
20-Day Prediction
+18.13%
$0.98
95% positive prob.
SEC 8-K filings with transcript text
Nov 14, 2025 · 100% conf.
1D
+11.96%
$0.93
Act: -20.28%
5D
+23.99%
$1.03
Act: -3.48%
20D
+18.13%
$0.98
8-K
false 0001865494 0001865494 2025-11-14 2025-11-14
PURSUANT TO SECTION 13 OR 15(d)
Date of Report (Date of earliest event reported): November 14, 2025
(Exact name of Registrant as Specified in its Charter)
Delaware
001-41008
87-0909276
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
Ole Maaløes Vej 3 DK-2200 Copenhagen N Denmark (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: +45 7070 2980 N/A (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On November 14, 2025, IO Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended September 30, 2025 and an update on the Company’s operations for the same period. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information included in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
99.1
Press Release of the Company dated November 14, 2025
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 14, 2025
By:
/s/ Mai-Britt Zocca
Name:
Mai-Britt Zocca, Ph.D.
Title:
Chief Executive Officer
Aug 14, 2025
8-K
false 0001865494 0001865494 2025-08-14 2025-08-14
PURSUANT TO SECTION 13 OR 15(d)
Date of Report (Date of earliest event reported): August 14, 2025
(Exact name of Registrant as Specified in its Charter)
Delaware
001-41008
87-0909276
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
Ole Maaløes Vej 3 DK-2200 Copenhagen N Denmark (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: +45 7070 2980 N/A (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On August 14, 2025, IO Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended June 30, 2025 and an update on the Company’s operations for the same period. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information included in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
99.1
Press Release of the Company dated August 14, 2025
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 14, 2025
By:
/s/ Mai-Britt Zocca
Name:
Mai-Britt Zocca, Ph.D.
Title:
Chief Executive Officer
Aug 11, 2025
8-K
false 0001865494 0001865494 2025-08-11 2025-08-11
Date of Report (Date of earliest event reported): August 11, 2025
(Exact name of Registrant as Specified in its Charter)
Delaware
001-41008
87-0909276
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
Ole Maaløes Vej 3
DK-2200 Copenhagen N
Denmark
(Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: +45 7070 2980 N/A (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
As discussed below, IO Biotech, Inc., a Delaware corporation (the “Company”), is hosting a conference call and webcast, during which the Company will make a slide presentation. In the slide presentation, the Company is disclosing an estimated cash and cash equivalents balance of approximately $28.1 million as of June 30, 2025, and further disclosing that the Company estimates that these cash and cash equivalents, plus the €12.5 million drawn on July 4, 2025 from the second tranche of the term loan facility with the European Investment Bank, will be sufficient to meet its working capital requirements into the first quarter of 2026. Because the Company’s financial closing procedures as of and for the six months ended June 30, 2025, are not yet complete, its final results upon completion of those procedures may differ materially from its preliminary estimate. Accordingly, you should not place undue reliance on this preliminary estimate.
Item 7.01. Regulation FD Disclosure.
On August 11, 2025, the Company issued a press release announcing topline results from IOB-013, the Company’s Phase 3 trial of Cylembio® in combination with pembrolizumab as a first-line treatment for patients with unresectable or metastatic (advanced) melanoma. The Company is hosting a conference call and webcast at 8:30 am Eastern Time, on August 11, 2025, during which the Company will discuss the topline results and will make a slide presentation. The press release is attached as Exhibit 99.1 and the form of slide presentation is attached as Exhibit 99.2, and each is incorporated into this Item 8.01 by reference. The information contained in this Current Report on Form 8-K is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 8.01. Other Events
The randomized, open-label study enrolled 407 patients across more than 100 sites worldwide. Patients received either Cylembio in combination with pembrolizumab (n=203) or pembrolizumab alone (n=204). The primary endpoint was PFS as assessed by a blinded independent review committee per RECIST v1.1. The early and sustained separation of PFS curves demonstrated an improvement with a hazard ratio of 0.77 [95% CI: 0.58-1.00; p=0.056; threshold for significance p≤0.045]. Based on an intent-to-treat analysis, patients in the study treated with Cylembio in combination with pembrolizumab achieved 19.4 months of median progression free survival compared to 11.0 months in patients treated with pembrolizumab alone. Although not yet ma
May 14, 2025
8-K
false 0001865494 0001865494 2025-05-14 2025-05-14
PURSUANT TO SECTION 13 OR 15(d)
Date of Report (Date of earliest event reported): May 14, 2025
(Exact name of Registrant as Specified in its Charter)
Delaware
001-41008
87-0909276
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
Ole Maaløes Vej 3 DK-2200 Copenhagen N Denmark (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: +45 7070 2980 N/A (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On May 14, 2025, IO Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended March 31, 2025 and an update on the Company’s operations for the same period. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information included in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
99.1
Press Release of the Company dated May 14, 2025
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 14, 2025
By:
/s/ Mai-Britt Zocca
Name:
Mai-Britt Zocca, Ph.D.
Title:
Chief Executive Officer
Mar 4, 2025
8-K
false 0001865494 0001865494 2025-03-04 2025-03-04
Date of Report (Date of earliest event reported): March 4, 2025
(Exact name of Registrant as Specified in its Charter)
Delaware
001-41008
87-0909276
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.) Ole Maaløes Vej 3 DK-2200 Copenhagen N Denmark (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: +45 7070 2980 N/A (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
As discussed below, IO Biotech, Inc., a Delaware corporation (the “Company”), issued a press release on March 4, 2025. In its press release, the Company disclosed a cash and cash equivalents balance of approximately $60 million as of December 31, 2024. Because the Company’s consolidated financial statements for the year ended December 31, 2024 have not yet been finalized or audited, the preliminary statement of the Company’s cash and cash equivalents as of December 31, 2024 in this Item 2.02 is subject to change, and the Company’s actual cash and cash equivalents as of December 31, 2024 may differ materially from this preliminary estimate. Accordingly, you should not place undue reliance on this preliminary estimate.
Item 7.01. Regulation FD Disclosure.
On March 4, 2025, the Company issued a press release providing business updates (the “Press Release”). The Press Release primarily includes updates on the Company’s ongoing and planned clinical trials and disclosures regarding the Company’s cash and cash equivalents as of December 31, 2024. A copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated by reference into this Item 7.01 of this Current Report on Form 8-K. The information contained in this Current Report on Form 8-K is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit Number
Exhibit Description
99.1
IO Biotech, Inc. Press Release, dated as of March 4, 2025
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 4, 2025
By:
/s/ Mai-Britt Zocca, Ph.D.
Name:
Mai-Britt Zocca, Ph.D.
Title:
Chief Executive Officer
Nov 12, 2024
8-K
false 0001865494 0001865494 2024-11-12 2024-11-12
PURSUANT TO SECTION 13 OR 15(d)
Date of Report (Date of earliest event reported): November 12, 2024
(Exact name of Registrant as Specified in its Charter)
Delaware
001-41008
87-0909276
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
Ole Maaløes Vej 3 DK-2200 Copenhagen N Denmark (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: +45 7070 2980 N/A (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On November 12, 2024, IO Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended September 30, 2024 and an update on the Company’s operations for the same period. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information included in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
99.1
Press Release of the Company dated November 12, 2024
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 12, 2024
By:
/s/ Mai-Britt Zocca
Name:
Mai-Britt Zocca, Ph.D.
Title:
Chief Executive Officer
Aug 13, 2024
8-K
false 0001865494 0001865494 2024-08-13 2024-08-13
PURSUANT TO SECTION 13 OR 15(d)
Date of Report (Date of earliest event reported): August 13, 2024
(Exact name of Registrant as Specified in its Charter)
Delaware
001-41008
87-0909276
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
Ole Maaløes Vej 3 DK-2200 Copenhagen N Denmark (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: +45 7070 2980 N/A (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On August 13, 2024, IO Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended June 30, 2024 and an update on the Company’s operations for the same period. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information included in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
99.1
Press Release of the Company dated August 13, 2024
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 13, 2024
By:
/s/ Mai-Britt Zocca
Name:
Mai-Britt Zocca, Ph.D.
Title:
Chief Executive Officer
May 14, 2024
8-K
false 0001865494 0001865494 2024-05-14 2024-05-14
PURSUANT TO SECTION 13 OR 15(d)
Date of Report (Date of earliest event reported): May 14, 2024
(Exact name of Registrant as Specified in its Charter)
Delaware
001-41008
87-0909276
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
Ole Maaløes Vej 3 DK-2200 Copenhagen N Denmark (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: +45 7070 2980 N/A (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On May 14, 2024, IO Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended March 31, 2024 and an update on the Company’s operations for the same period. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information included in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
99.1
Press Release of the Company dated May 14, 2024
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 14, 2024
By:
/s/ Mai-Britt Zocca
Name:
Mai-Britt Zocca, Ph.D.
Title:
Chief Executive Officer
Mar 5, 2024
8-K
false 0001865494 0001865494 2024-03-05 2024-03-05
PURSUANT TO SECTION 13 OR 15(d)
Date of Report (Date of earliest event reported): March 5, 2024
(Exact name of Registrant as Specified in its Charter)
Delaware
001-41008
87-0909276
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
Ole Maaløes Vej 3 DK-2200 Copenhagen N Denmark (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: +45 7070 2980 N/A (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On March 5, 2024, IO Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2023 and an update on the Company’s operations for the same period. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. The information included in this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
99.1
Press Release of the Company dated March 5, 2024
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 5, 2024
By:
/s/ Mai-Britt Zocca
Name:
Mai-Britt Zocca, Ph.D.
Title:
Chief Executive Officer
Nov 13, 2023
8-K
false 0001865494 0001865494 2023-11-09 2023-11-09
Date of Report (Date of earliest event reported): November 9, 2023
(Exact name of Registrant as Specified in its Charter)
Delaware
001-41008
87-0909276
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
Ole Maaløes Vej 3 DK-2200 Copenhagen N Denmark (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: +45 7070 2980 N/A (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On November 13, 2023, IO Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023 and an update on the Company’s operations for the same period. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1.
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On November 9, 2023, the Company increased the size of the Board from seven to eight directors, and appointed Helen Collins, M.D. as a Class II director of the Company to fill the vacancy, effective as of that same date. The Board also appointed Dr. Collins to serve as the Chairperson of the Board’s Research and Development Committee, which was established by the Board on November 9, 2023. There are no arrangements or understandings between Dr. Collins and any other person pursuant to which Dr. Collins was selected as a director. There are no transactions involving Ms. Hunter that would be required to be reported under Item 404(a) of Regulation S-K. In connection with her appointment as a director of the Company, Dr. Collins will enter into the Company’s standard indemnification agreement applicable to non-employee directors and will be eligible for compensation in accordance with the Company’s Non-Employee Directors’ Compensation Policy (the “Policy”), as described in the Company’s Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 26, 2023. In addition, at the close of business on November 15, 2023, Dr. Collins will receive a grant of 64,238 stock options. The stock options will vest monthly over three years, subject to Ms. Hunter’s continuous service on each applicable vesting date. All stock options are to be settled in shares of the Company’s common stock. Like other eligible directors, Dr. Collins will be eligible to receive subsequent stock option awards if she is continuing her service on the Board of Directors of the Company following each annual meeting of stockholders. In accordance with the Policy, the value of such subsequent awards of stock option grants shall be $75,000 as of the grant date and will vest upon the one-year anniversary of the grant date, subject to Dr. Collins’ continuous service until such date. Notwithstanding the vesting schedules described above, if Dr. Collins remains in continuous service until a change of control of the Company, she will become fully vested in all of her then-outstanding equity awards.
Item 7.01. Regulation FD Disclosure.
On November 13, 2023, the Company issued a press release announcing Dr. Collins’ appointment. A copy of the press release is attached hereto as Exhibit 99.2. The information contained in this Current Report on
Aug 11, 2023
8-K
false 0001865494 0001865494 2023-08-07 2023-08-07
Date of Report (Date of earliest event reported): August 7, 2023
(Exact name of Registrant as Specified in its Charter)
Delaware
001-41008
87-0909276
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
Ole Maaløes Vej 3 DK-2200 Copenhagen N Denmark (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: +45 7070 2980 N/A (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On August 11, 2023, IO Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023 and an update on the Company’s operations for the same period. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1.
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August 8, 2023, the Company appointed Heidi Hunter as a Class II director of the Company, effective as of August 11, 2023. The Board also appointed Ms. Hunter to serve on the Board’s Audit Committee and Nominating and Corporate Governance Committee. There are no arrangements or understandings between Ms. Hunter and any other person pursuant to which Ms. Hunter was selected as a director. There are no transactions involving Ms. Hunter that would be required to be reported under Item 404(a) of Regulation S-K. In connection with her appointment as a director of the Company, Ms. Hunter will enter into the Company’s standard indemnification agreement applicable to non-employee directors and will be eligible for compensation in accordance with the Company’s Non-Employee Directors’ Compensation Policy (the “Policy”), as described in the Company’s Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 26, 2023. In addition, at the close of business on August 11, 2023, Ms. Hunter will receive a grant of 64,238 stock options. The stock options will vest monthly over three years, subject to Ms. Hunter’s continuous service on each applicable vesting date. All stock options are to be settled in shares of the Company’s common stock. Like other eligible directors, Ms. Hunter will be eligible to receive subsequent stock option awards if she is continuing her service on the Board of Directors of the Company following each annual meeting of stockholders. In accordance with the Policy, the value of such subsequent awards of stock option grants shall be $75,000 as of the grant date and will vest upon the one-year anniversary of the grant date, subject to Ms. Hunter’s continuous service until such date. Notwithstanding the vesting schedules described above, if Ms. Hunter remains in continuous service until a change of control of the Company, she will become fully vested in all of her then-outstanding equity awards. On August 7, 2023, Priyanka Belawat, a member of the Board of Directors of the Company, notified the Company of her resignation from the Board, effective that same date. Ms. Belawat’s decision is not due to any disagreement with the Company or the Board on any matter relating to the Company’s operations, policies or practices.
Item 7.01. Regulation FD Disclosure.
On August 11, 2023, the Company issued a
May 11, 2023
8-K
false 0001865494 0001865494 2023-05-11 2023-05-11
PURSUANT TO SECTION 13 OR 15(d)
Date of Report (Date of earliest event reported): May 11, 2023
(Exact name of Registrant as Specified in its Charter)
Delaware
001-41008
87-0909276
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
Ole Maaløes Vej 3 DK-2200 Copenhagen N Denmark (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: +45 7070 2980 N/A (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On May 11, 2023, IO Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended March 31, 2023 and an update on the Company’s operations for the same period. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information included in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
99.1
Press Release of the Company dated May 11, 2023
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 11, 2023
By:
/s/ Mai-Britt Zocca
Name:
Mai-Britt Zocca, Ph.D.
Title:
Chief Executive Officer
Mar 14, 2023
8-K
false 0001865494 0001865494 2023-03-14 2023-03-14
PURSUANT TO SECTION 13 OR 15(d)
Date of Report (Date of earliest event reported): March 14, 2023
(Exact name of Registrant as Specified in its Charter)
Delaware
001-41008
87-0909276
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
Ole Maaløes Vej 3 DK-2200 Copenhagen N Denmark (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: +45 7070 2980 N/A (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On March 14, 2023, IO Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2022 and an update on the Company’s operations for the same period. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information included in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
99.1
Press Release of the Company dated March 14, 2023
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 14, 2023
By:
/s/ Mai-Britt Zocca
Name:
Mai-Britt Zocca, Ph.D.
Title:
Chief Executive Officer
Mar 14, 2023
8-K
false 0001865494 0001865494 2023-03-14 2023-03-14
Date of Report (Date of earliest event reported): March 14, 2023
(Exact name of Registrant as Specified in its Charter)
Delaware
001-41008
87-0909276
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
Ole Maaløes Vej 3 DK-2200 Copenhagen N Denmark (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: +45 7070 2980 N/A (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
As discussed below, in connection with its participation in the Oppenheimer 33rd Annual Healthcare Conference (the “Conference”) taking place virtually, IO Biotech, Inc., a Delaware corporation (the “Company”), updated its corporate presentation to include disclosure that the Company had approximately $142 million of cash and cash equivalents as of December 31, 2022. Because the Company’s consolidated financial statements for the year ended December 31, 2022 have not been finalized or audited, the preliminary statement of the Company’s cash and cash equivalents as of December 31, 2022 in this Item 2.02 is subject to change, and the Company’s actual cash and cash equivalents as of December 31, 2022 may differ materially from this preliminary estimate. Accordingly, you should not place undue reliance on this preliminary estimate.
Item 7.01. Regulation FD Disclosure.
Beginning on March 14, 2023, the Company will participate in the Conference. The Company has updated its corporate presentation that it intends to use in connection with its presentation at the Conference and in meetings with investors. The presentation includes, among other things, an update regarding the Company’s clinical progress, disclosure regarding the Company’s cash and cash equivalents as of December 31, 2022 and confirmation of its projected cash runway through the third quarter of 2024. A copy of the Company’s corporate presentation is attached hereto as Exhibit 99.1 and is hereby incorporated by reference herein. The information furnished under Item 2.02 and Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits:
Exhibit Number
Exhibit Description
99.1
IO Biotech, Inc., Investor Deck, dated as of March 14, 2023
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 14, 2023
By:
/s/ Mai-Britt Zocca, Ph.D.
Name:
Mai-Britt Zocca, Ph.D.
Title:
Chief Executive Officer
Jan 9, 2023
8-K
false 0001865494 0001865494 2023-01-09 2023-01-09
Date of Report (Date of earliest event reported): January 9, 2023
(Exact name of Registrant as Specified in its Charter)
Delaware
001-41008
87-0909276
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
Ole Maaløes Vej 3 DK-2200 Copenhagen N Denmark (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: +45 7070 2980 N/A (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
As discussed below, IO Biotech, Inc., a Delaware corporation (the “Company”), issued a press release on January 9, 2023. In its press release, the Company disclosed a cash and cash equivalents balance of approximately $142.7 million as of December 31, 2022. Because the Company’s consolidated financial statements for the year ended December 31, 2022 have not yet been finalized or audited, the preliminary statement of the Company’s cash and cash equivalents as of December 31, 2022 in this Item 2.02 is subject to change, and the Company’s actual cash and cash equivalents as of December 31, 2022 may differ materially from this preliminary estimate. Accordingly, you should not place undue reliance on this preliminary estimate.
Item 7.01. Regulation FD Disclosure.
On January 9, 2023, the Company issued a press release providing business updates (the “Press Release”). The press release primarily includes updates on the Company’s ongoing and planned clinical trials and disclosure regarding the Company’s cash and cash equivalents as of December 31, 2022. Beginning on January 9, 2023, the Company will participate in the 41st Annual J.P. Morgan Healthcare Conference. In connection with its participation, on January 9, 2023, the Company posted to the “Investor Relations” section of the Company’s website at www.investors.iobiotech.com a corporate presentation providing an update of the Company’s current business and products (the “Investor Deck”). Copies of the Press Release and Investor Deck are attached hereto as Exhibits 99.1 and 99.2 respectively and are incorporated by reference into this Item 7.01 of this Current Report on Form 8-K. The information contained in this Current Report on Form 8-K is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit Number
Exhibit Description
99.1
IO Biotech, Inc., Investor Deck, released on January 9, 2023
99.2
IO Biotech, Inc., Press Release, dated as of January 9, 2023
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: January 9, 2023
By:
/s/ Mai-Britt Zocca, Ph.D.
Name:
Mai-Britt Zocca, Ph.D.
Title:
Chief Executive Officer
Nov 9, 2022
8-K
false 0001865494 0001865494 2022-11-09 2022-11-09
PURSUANT TO SECTION 13 OR 15(d)
Date of Report (Date of earliest event reported): November 9, 2022
(Exact name of Registrant as Specified in its Charter)
Delaware
001-41008
87-0909276
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
Ole Maaløes Vej 3 DK-2200 Copenhagen N Denmark (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: +45 7070 2980 N/A (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On November 9, 2022, IO Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022 and an update on the Company’s operations for the same period. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information included in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
99.1
Press Release of the Company, dated November 9, 2022
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 9, 2022
By:
/s/ Mai-Britt Zocca
Name:
Mai-Britt Zocca, Ph.D.
Title:
Chief Executive Officer
Aug 11, 2022
8-K
false 0001865494 0001865494 2022-08-11 2022-08-11
PURSUANT TO SECTION 13 OR 15(d)
Date of Report (Date of earliest event reported): August 11, 2022
(Exact name of Registrant as Specified in its Charter)
Delaware
001-41008
87-0909276
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
Ole Maaløes Vej 3 DK-2200 Copenhagen N Denmark (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: +45 7070 2980 N/A (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On August 11, 2022, IO Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2022 and an update on the Company’s operations for the same period. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information included in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
99.1
Press Release of the Company, dated August 11, 2022
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 11, 2022
By:
/s/ Mai-Britt Zocca
Name:
Mai-Britt Zocca, Ph.D.
Title:
Chief Executive Officer
May 16, 2022
8-K
false 0001865494 0001865494 2022-05-16 2022-05-16
PURSUANT TO SECTION 13 OR 15(d)
Date of Report (Date of earliest event reported): May 16, 2022
(Exact name of Registrant as Specified in its Charter)
Delaware
001-41008
87-0909276
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
Ole Maaløes Vej 3 DK-2200 Copenhagen N Denmark
(Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: +45 7070 2980 N/A (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On May 16, 2022, IO Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2022 and an update on the Company’s operations for the same period. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information included in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
99.1
Press Release of the Company, dated May 16, 2022
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 16, 2022
By:
/s/ Mai-Britt Zocca
Name:
Mai-Britt Zocca, Ph.D.
Title:
Chief Executive Officer
Mar 31, 2022
8-K
false 0001865494 0001865494 2022-03-31 2022-03-31
PURSUANT TO SECTION 13 OR 15(d)
Date of Report (Date of earliest event reported): March 31, 2022
(Exact name of Registrant as Specified in its Charter)
Delaware
001-41008
87-0909276
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
Ole Maaløes Vej 3 DK-2200 Copenhagen N Denmark (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: +45 7070 2980 N/A (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition On March 31, 2022, IO Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2021 and an update on the Company’s operations for the same period. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information included in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits
Exhibit No.
Description
99.1
Press Release of the Company dated March 31, 2022
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 31, 2022
By:
/s/ Mai-Britt Zocca
Name:
Mai-Britt Zocca, Ph.D.
Title:
Chief Executive Officer
Dec 17, 2021
8-K 1 d267306d8k.htm 8-K
8-K
PURSUANT TO SECTION 13 OR 15(d)
Date of Report (Date of earliest event reported): December 13, 2021
(Exact name of Registrant as Specified in its Charter)
Delaware
001-41008
87-0909276
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
Ole Maaløes Vej 3
DK-2200 Copenhagen N
Denmark (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: +45 7070 2980
N/A (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange
on which registered
Common Stock, par value $0.001 per share
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Result of Operations and Financial Condition
The information set forth under Item 4.02 is incorporated into this Item 2.02 by reference.
Item 4.02(a) Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review. On December 13, 2021, the Audit Committee of the Board of Directors of IO Biotech, Inc. (the “Company”), based on the recommendation of management and after consultation with the Company’s independent registered public accounting firm, EY Godkendt Revisionspartnerselskab (EY), determined that the Company’s Unaudited Interim Condensed Financial Statements as of June 30, 2021 and for the Six Months Ended June 30, 2021 and 2020 (the “Relevant Financial Statements”) incorrectly accounted for an accrued expense related to certain research and development expenses, which should have been recorded as a prepaid expense. This led to an overstatement of research and development expenses for the six months ended June 30, 2021. This incorrect accrued expense does not impact:
•
total research and development expenses for the 9-month period ending September 30, 2021 nor the financial year ended December 31, 2021
•
the cash balances reported as of June 30, 2021 or any other period
•
the timing or magnitude of cash used in operations for the six months period ending June 30, 2021
•
the Company’s previous guidance related to its cash runway
•
any other prior periods other than the Relevant Financial Statements
Consequently, on December 13, 2021, the Audit Committee concluded that investors should not rely on the Company’s unaudited interim condensed financial statements as of June 30, 2021 and for the six months ended June 30, 2021, originally filed with the Securities and Exchange Commission (“SEC”) on October 5, 2021. The Company is filing the above-described restated unaudited Relevant Financial Statements as an exhibit to this Current Report on Form 8-K. The Audit Committee has discussed the matters disclosed in this Current Report on Form 8-K with EY, the Company’s independent registered public accounting firm.
The tables below show the impact of the restatements on the relevant line items in the Company’s financial statements:
Balance Sheet (In thousands, except per share data) (unaudited)
As of June 30, 2021
As reported
Adjustment
As restated
Prepaid expenses and other current assets
$ 3,744
$ 1,666
$ 5,410
Total current assets
58,496
1,666
60,162
Total assets
58,534
1,666
60,200
Accrued expenses and other current liabilities
5,915
(1,666 )
4,249
Total liabilities
38,955
(1,666 )
37,289
Accumulated deficit
(83,878 )
3,369
(80,509 )
Accumulated other comprehensive income
1,422
(37 )
1,385
Total stockholders’ deficit
(81,309 )
3,332
(77,977 )
Total liabilities, convertible preference shares and stockholders’ deficit
58,534
1,666
60,200
Statement of Operations and Com
This page provides IO Biotech Inc. (IOBT) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on IOBT's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.